Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Hello. It’s James Altucher.
Are you seeing the big crypto moves out of the Trump Administration?
Now, New Hampshire just became the first state to create a Strategic Crypto Reserve.
It all tells me only one thing:
Trump’s Great Gain is finally starting.
I predicted it right after his inauguration…
And it appears I was right.
The Great Gain is now starting.
If you get in before August 30th…
The upcoming months could be perhaps the best time in our nation’s history…
For regular Americans to get rich.
I believe you could turn a modest investment of say $900…
Into as much as $108,000 in just the next 12 months.
But Trump’s Great Gain won’t happen again, so get in while you still can.
And be sure to get in before August 30th for your BEST chance to profit.
I will show you everything you need to know…
When you click here right now.
To your good fortune,
James Altucher
Best-selling author; former hedge fund manager; self-made millionaire
P.S. I urge you: Do not miss out on Trump’s Great Gain. After August 30th it may be too late. Click here to see my Great Gain gameplan now.
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
Written by Ryan Hasson. Published 8/29/2025.
Key Points
- Incyte delivered a blowout Q2 with revenue and earnings exceeding expectations.
- The company is advancing late-stage candidates, such as INCA033989 and Povrocitinib, which could diversify revenue and reduce dependence on Jakafi.
- Analysts expect nearly 450% EPS growth in 2025, making execution on its core portfolio and pipeline critical for sustaining the outperformance experienced so far YTD.
During a year when healthcare stocks, particularly biotechnology, have lagged the broader market, it's notable that Incyte Corporation (NASDAQ: INCY) has outperformed. The stock is up 21.6% year-to-date, outpacing both its sector peers and the S&P 500.
This resilience stems from a stellar second-quarter earnings report and optimistic management commentary. As Incyte nears a potential multi-year breakout, the key question is whether it can deliver on its ambitious earnings forecasts and pipeline promises.
Q2 Results Exceed Expectations
IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead? (Ad)
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers.
But the wealthy aren't just writing checks. They're moving fast to protect capital and purchasing power using legal, IRS-compliant strategies.
American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it's drained.
Incyte's latest quarterly results ignited its recent rally. The company reported Q2 revenue of $1.22 billion, topping consensus of $1.15 billion and marking 16.5% year-over-year growth. Adjusted earnings per share came in at $1.57, a 6.5% beat, while adjusted EBITDA reached $553.2 million, outstripping forecasts by 63.5%.
Operating margin jumped to 43.6%, compared to a loss in the same quarter last year. Management credited the strong performance to robust demand for its blockbuster drug Jakafi, accelerating adoption of Opzelura, and early momentum for Niktimvo in bone marrow transplant centers.
A Strong Core and Expanding Pipeline
Beyond the quarter, Incyte's strategy focuses on maximizing its core commercial franchises while advancing a robust pipeline in hematology-oncology and immunology.
Jakafi remains the flagship therapy for myeloproliferative neoplasms, with potential expansion into chronic graft-versus-host disease. Opzelura, the topical ruxolitinib cream, continues to gain traction in atopic dermatitis and vitiligo, and upcoming pediatric studies and international launches could further boost its market presence. Meanwhile, Niktimvo—approved in 2024 for chronic graft-versus-host disease—is gathering momentum and may enter frontline treatment settings through combination trials, significantly expanding its opportunity.
These three products are expected to underpin Incyte's near-term growth, while its late-stage pipeline aims to drive the next wave of expansion. The company highlights several late-stage assets that could prove transformational. INCA033989, which targets calreticulin-mutated myeloproliferative neoplasms, delivered encouraging Phase I results in essential thrombocythemia and is moving into pivotal trials for both ET and myelofibrosis. Povorcitinib, a JAK1 inhibitor, reported positive Phase 3 results in hidradenitis suppurativa and is expected to advance toward regulatory filings in 2026. Successful launches of these candidates would diversify Incyte's revenue beyond Jakafi and reduce reliance on its current blockbuster as patents near expiration.
Can Incyte Live Up to Lofty Expectations?
Analysts forecast an extraordinary earnings trajectory, with full-year EPS for 2025 expected to grow nearly 450% from the prior year. This bold estimate reflects both Incyte's turnaround in profitability and expectations for continued operational momentum.
With strong first-half results and favorable guidance, Incyte appears on track to meet—and perhaps exceed—these ambitious projections. The company has also snapped its recent streak of missing estimates, restoring confidence in its execution.
Nevertheless, risks remain, including the inherent challenges of biopharmaceutical development, such as meeting primary endpoints and securing regulatory approvals.
Ultimately, Incyte's ability to sustain its rally and achieve a multi-year breakout hinges on three critical factors: maintaining strength in its commercial portfolio, delivering on pipeline milestones, and exercising disciplined financial management amid industry headwinds. If management can execute on these fronts, the combination of robust earnings growth and a deepening pipeline could cement this breakout as more than just a short-term move.
to bring you the latest market-moving news.
This email message is a sponsored message provided by Paradigm Press, a third-party advertiser of TickerReport and MarketBeat.
This ad is sent on behalf of Paradigm Press, LLC dba TickerReport, at 1001 Cathedral St., Baltimore, MD 21201. If you're not interested in this opportunity from Paradigm Press, LLC dba TickerReport, please click here to remove your email from these offers.
Contact Us | Unsubscribe
© 2006-2025 MarketBeat Media, LLC dba TickerReport. All rights protected.
345 North Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. United States..
No comments:
Post a Comment